NasdaqCM:IMNMBiotechs
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors
Immunome, Inc. recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, updating investors on its oncology-focused pipeline and regulatory plans.
A key highlight is the company’s push toward a New Drug Application for Varegacestat in desmoid tumors, alongside multiple upcoming solid tumor IND submissions and an FDA-cleared radioligand therapy trial.
We’ll now examine how Immunome’s renewed oncology focus and advancing Varegacestat program might influence the company’s...